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Background: Polysensitisation is common in patients with respiratory allergy in Spain. Selection of the best
allergen immunotherapy (AIT) is difficult in polysensitised patients. The present study was designed to help
allergists better identify relevant allergens in these patients and to improve the selection of AIT in Spain.
Methods: Sixty-two Spanish allergists answered a survey containing 88 items divided into four groups: 1) general
approach to polysensitised subjects; 2) sensitisation profile involving mite, animal dander and moulds; 3) grass and
olive pollen co-sensitisation, and 4) other pollen polysensitisation profile (weed and tree pollen). The Delphi method
was used.
Results: A consensus was achieved for 83% of items (92%, 81%, 83% and 73% of the four groups analysed,
respectively). Only polysensitised patients with clinical relevance should be considered polyallergic. A detailed
medical history (clinical symptoms and medication) together with a profound knowledge of allergens present in
the patient’s environment are essential for diagnosis. Skin prick tests (SPTs) are not adequate to decide the clinical
relevance of each allergen. Serum specific IgE against allergen sources adds value to SPT but molecular diagnosis,
when possible, is strongly recommended, especially in pollen-allergic patients. Specific allergen challenge tests are
difficult to perform and not recommended for daily practice. Regarding AIT composition, up to three allergens can
be used in the same vaccine, but only related allergens may be mixed. In some cases more than one vaccine may
be needed.
Conclusion: Some criteria have been established to improve diagnosis and AIT prescription in polysensitised
patients.
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Respiratory allergy represents an overall public health
problem because of its prevalence, morbidity, impact on
quality of life and cost [1-4]. Pollen [5,6] and house-dust
mites (HDM) [7] are the most common allergens related
to respiratory diseases, followed by animal dander and
moulds [8]. Polysensitisation, defined as the presence of
more than one specific IgE sensitisation against non-
related allergen sources, is frequent in Spain [6]. However,* Correspondence: carmen.vidal.pan@sergas.es
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unless otherwise stated.the exact clinical relevance of each sensitisation is some-
times difficult to establish and, consequently, allergists
may have difficulty in deciding which is the most appro-
priate composition for allergen immunotherapy (AIT) for
each patient. For this purpose, the recognition of the sen-
sitisation profile (identification of primary sensitisation
markers with respect to detection of specific IgE against
cross-reactive allergen molecules) has been suggested as a
tool to define better the relevant or irrelevant allergens in
each patient [5].
The efficacy of AIT in monosensitised patients has been
proven in both children and adults and with both routes
of administration, subcutaneous (SCIT) and sublinguald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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approach to polysensitised subjects. Thus, while monoal-
lergen AIT is preferred in European countries, the use of
more than eight allergens in the same vaccine is common
in the US [12]. In this regard, the European Medicine
Agency (EMA) recommends that allergists restrict the
mixture of non-related allergens to a minimum and ad-
vises not to mix seasonal and perennial allergens, or aller-
gens with proteolytic activity without justification [13].
Taking these concepts together, define precisely the diag-
nosis seems important before prescribing AIT [14]. The
present study was designed to explore the medical opinion
of a panel of 62 Spanish allergists in order to achieve
consensus regarding diagnosis and treatment with AIT
in polysensitised patients, aiming to improve allergic
treatment.
Methods
To investigate the opinion of a sample of 62 allergists
from Spain (Figure 1), a modified Delphi method [15]
was used. First, a steering committee of five allergists
(authors of this manuscript) reviewed the medical litera-
ture on the topic and discussed the main items to be in-
cluded in a structured questionnaire. Fifty-seven more
allergists with a solid clinical experience in AIT in adults
and/or children and a teaching clinical practice of AIT
in fellows in training and in continuing medical educa-
tion Spanish programmes were selected by the steeringFigure 1 Distribution of Spanish allergist who took part in the consencommittee. This selection process began with a specific
proposal from each member of the steering committee,
who named 30 allergists throughout the country known
for their interest in AIT to work on the project. All
names repeated at least twice were included as “panelists
by agreement”. The steering committee together with
this team of allergists defined the final questionnaire.
Questionnaire and Delphi methodology
The final version of the questionnaire included 88 items
distributed in four topics: 1) general approach to polysensi-
tised subjects (n = 24) (Table 1); 2) sensitisation profile
regarding mite, animal dander and moulds (n = 26)
(Table 2); 3) grass and olive pollen co-sensitisation (n = 18)
(Table 3), and 4) other pollen polysensitisation profile
(n = 20) (Table 4) representing the main geographical
patterns of sensitisation in Spain. For all topics including
allergens, items were grouped according to epidemiology,
clinical relevance and therapeutic strategy (Tables 2A, 3A
and 4A). An independent team, consisting of 3 non-
medical people worked as facilitators, requesting the
opinion of each allergist, using the online survey (88 items),
on an individual and anonymous basis. Answers were
collected from May 2013 to June 2013. After analysing the
results of the first round, one of the facilitators provided an
anonymous summary of the forecasts as well as the reasons
allergists provided for their judgements. Thus, allergists
were encouraged to revise their earlier answers in light ofsus.
Table 1 Items included in the questionnaire about “General approach to polysensitized subjects” (1A) and results (1B)
1A) 1B)
Items Mean Median % Panellists against IQ Result
Diagnostic approach to a patient with suspected respiratory allergy
1- Skin-tests are sufficient for the correct aetiologic diagnosis of patients with respiratory
allergy
3.08 3 32.26 2 D
2- The size of the wheal is useful in the clinically relevant allergen identification 3.75 3 35 2.5 NC
3- A positive skin-test indicates the clinical relevance of the allergenic source 2.11 2 9.68 1.5 D
4- The specific IgE determination and quantification help us to establish the clinical
relevance of an allergenic source
6.22 7 28.33 1 A
5- Molecular diagnosis serves to differentiate primary sensitisation from cross-reactivity 7.84 8 6.45 1 A
6- In molecular diagnostic tests, a cut-off that allows us to differentiate relevant allergens
does not exist
6.97 7 27.42 2 A
7- The patient diagnostic approach must be similar, independent of whether respiratory
symptoms are persistent or intermittent
6.92 8 25.81 3 A
8- The directed medical history and symptoms-exposure schedule allows us to identify
the responsible allergenic source of the patient’s clinic in some cases
7 7 11.67 0 A
9- Organ-specific provocation tests are not useful in daily clinical practice due to their
difficult interpretation and because they are time consuming
7.1 8 16.67 1 A
10a- The polysensitised patient is one who presents sensitisation to various allergenic
sources
7.47 8 11.67 2 A
10b- The polyallergic patient is one who presents sensitisation with demonstrated clinical
relevance
7.90 8 8.33 1 A
11- The aerobiological information should include the allergenic load in the environment 7.42 8 14.52 1 A
Determinant criteria in immunotherapy prescription
12- Before immunotherapy prescription to a polysensitised patient, an organ-specific
provocation with all suspected relevant allergens must be conducted
2.4 2 17.74 2 D
13- Assessment of the intensity of symptoms and medication consumption in relation to
allergenic exposure should be habitual practice in immunotherapy prescription
8.23 8 1.61 1 A
14- Immunotherapy should only be used based on clinical studies that follow current
guidelines
6.92 7.5 29.03 2.5 A
15-Immunotherapy prescription is advised only if relevant allergen sources are identified 7.22 7 6.67 1 A
Immunotherapy composition
16- Enzymatic activity (proteolysis) over others should not be used 7.6 8 14.52 2 A
17- It is acceptable to include up to two or three allergens in one vaccine if their
relevance is identified
6.28 7 28.33 2 A
18- Immunotherapy should include all relevant allergenic sources 3.63 3 25 1 D
19- Safety studies of a given extract are applicable to all extracts from identical allergenic
sources
2.31 2 14.52 2 D
20- Efficacy studies of a given extract are assimilable to all extracts from identical
allergenic sources
2.55 2 17.74 2 D
21- The extract mixture has a nonspecific positive therapeutic effect despite dosage
reduction of included allergens
4.27 5 46.67 2 NC
22- If mixtures of several allergenic sources are used in immunotherapy, it is necessary to
ensure the effective concentration of each one in the final composition
7.89 8 6.45 2 A
24- The dose–response studies are conducted with vaccines from one allergenic source
so the results cannot be extrapolated to those of mixtures
7.16 8 22.58 1.5 A
A = Agreement; D = Disagreement; NC = No Consensus; IQ = Interquartile range.
% panellists = percentage of panellists out of the median region.
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round was performed dealing with those questions lacking.
A nine-point, single, ordinal, Likert-type scale was used to
assess the opinion on each item. Following Delphicategorization, responses were classified in three regions:
(1–3) = “disagree”; (4–6) = “neither agree nor disagree”;
(7–9) = “agreement”. The survey also offered the possibility of
adding individual explanatory observations to every answer.
Table 2 Items included in the questionnaire about “Allergy to mites, animal dander and moulds” (2A) and results (2B)
2A) 2B)
Items Mean Median % Panellists against IQ Result
Epidemiology
25- Knowledge of the predominant type of mites in a geographical area is useful in
defining the composition of immunotherapy in an allergic patient.
7.98 8 3.23 2 A
26- The moulds with the most epidemiological importance in respiratory allergy are
Aspergillus and Alternaria.
7.74 8 6.45 2 A
27- In patients with double sensitisation to mites and Alternaria, it is essential know if
there is exposure to both sources
7.18 8 22.58 2 A
Clinical relevance
28- Skin-tests, by themselves, are sufficient for the diagnosis of mite allergy, epithelia and
mould.
3.57 3 25 1.5 D
29- Skin-tests are sufficient for the immunotherapy prescription to mites, epithelium and
mould.
3.43 3 26.67 2 D
30- Quantitation of specific IgE in serum against full mite extract adds additional value to
the skin-test.
6.4 7 26.67 1.5 A
31- In order to know the true sensitisation profile of patients allergic to mites, molecular
diagnosis is necessary.
6.13 7 38.33 2 NC
32- The specific IgE determination in serum against Der p 1 and Der p 2 is useful if these
components have been quantified in the vaccine.
6.83 7 20 0.5 A
33- The IgE specific quantification to Dermatophagoides and/or Lepidoglyphus and/or
Blomia helps to decide AIT composition.
6.65 7 16.67 0 A
34- Alt a1 determination as primary sensitiser to Alternaria is recommended before AIT
prescription with this mould.
6.18 7 35 2 NC
35- Clinical relevance of double sensitisation to Alternaria and mites may be improved by
symptom’s calendar.
6.2 7 40 2 NC
Therapeutic strategy (AIT for mite sensitised patients)
36-Given the high cross-reactivity between Dermatophagoides pteronyssinus and farinae,
the choice of the species present in the vaccine is irrelevant.
6.45 7 26.67 2 A
37- Quantification of major molecular components (Der p 1 and Der p 2) in the vaccine
is mandatory
6.92 8 22.58 1 A
38- In case of sensitisation to Lepidoglyphus or Blomia in a patient allergic to
Dermatophagoides, only after proving clinical relevance of these minor mites should a
vaccine be indicated.
7.47 8 14.52 1 A
39- Vaccines containing minor mites should not be used until efficacy has been proven. 5.97 7 40 3 NC
40- In case of true allergy to both a minor mite and Dermatophagoides, a vaccine
containing both allergens could be used as a 50% mixture.
6.25 7 30 2 A
41- It is not advisable to mix mites with any other different allergenic source due to their
proteolytic activity
6.37 7 28.33 3 A
Therapeutic strategy (patient allergic to moulds (one or more) and with/without mite allergy)
42- Patients allergic to Alternaria only should receive a vaccine containing this allergenic
source.
7.69 8 11.29 2 A
43- Alternaria vaccine must have its major allergen quantified (Alt a 1) 7.95 8 11.29 2 A
44- Immunotherapy with mould mixtures is not indicated. 7.15 7 23.33 1 A
Therapeutic strategy (Regarding patients allergic to epithelia with/without other sensitivities)
45- There is not sufficient scientific evidence in immunotherapy to epithelia different
from cat and dog
5.02 6 86.67 4 NC
46- Studies with cat epithelium vaccine have shown clinical efficacy 7.76 8 9.68 2 A
47- In case of mite and epithelia sensitisation, both clinically relevant when animal
avoidance is not possible, a mixture of both would be advisable.
3.24 3 25.81 2 D
48- In case of mite and epithelia sensitisation, both clinically relevant when animal
avoidance is not possible, two vaccines should be used
6.74 7.2 32.26 2 A
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Table 2 Items included in the questionnaire about “Allergy to mites, animal dander and moulds” (2A) and results (2B)
(Continued)
49- In the same situation as previously described, the use of a vaccine containing one
allergen could be recommended followed by the consideration for a second AIT
7.37 8 19.35 2 A
50- In patients allergic to horse epithelium , when occupational exposure and/or severe
impact on quality of life is present, AIT could be considered
8.16 8 6.45 1 A
A = Agreement; D = Disagreement; NC = No Consensus; IQ = Interquartile range.
% panellists = percentage of panellists out of the median region.
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lysed. The median position of scores and the “level of agree-
ment or disagreement” [16] achieved was measured
according to the following criteria: an item is considered to
have consensus when no more than a third of the scores are
found outside of the region of three points (1–3),(4–6),(7–9)
where the median is located. In this case, the value of the
median score determines the group consensus reached:
“agreement” majority with medians ≥7; “disagreement”
majority with medians ≤3; “no consensus” items with
medians in the region 4–6 and when the scores of a third or
more of the participants are in the region 1–3, and another
third or more in the region 7–9. Also considered for
reassessment were the items where a high dispersion of opin-
ions (interquartile-range ≥ 4points) (Figure 2) was observed.Results
Detailed results of each item (mean, median, percentage of
distribution of respondents located outside the region of
the median, interquartile range and consensus result) are
depicted in Tables 1B, 2B, 3B and 4B. Overall, consensus
was reached in 73/88 items (83%), 55 of them (63%) were
in terms of agreement and the remaining 18 items (20%) in
terms of disagreement with the assertion presented.General approach to polysensitized subjects
Consensus was reached on 22/24 items, 16 in terms of
agreement and six items in terms of disagreement. Two
items were left without consensus. Specifically, when
considering the size of the wheal obtained in SPT,
some doctors supported its usefulness to define the
clinical relevance of an allergen while others did not.
Consequently, no consensus was achieved for this spe-
cific statement (item number 2, Table 1B). Even though
participants gave more value to serum specific IgE deter-
minations than to SPT for identifying clinically relevant
allergens, they seemed to rely more on molecular diagno-
sis but the lack of an exact cut-off level of serum specific
IgE against molecular compounds that could assist this
purpose is still not established. As regards to AIT, the
prescription should be based on scientific evidence and
only extracts with proven efficacy should be used. Vac-
cines containing up to two to three allergen sources could
be used if more than one allergen appears to be relevantbut no consensus was found when deciding if a mixture
has or not a nonspecific positive therapeutic effect.
Sensitisation profile involving mite, animal dander and
moulds
Consensus was reached on 21/26 items, 18 with overall
agreement and three in terms of disagreement. Consensus
was not reached on the remaining five items (Table 2B).
Thus, even though allergists think that serum specific IgE
against groups Der 1 and Der 2 could be helpful if these
allergens are quantified in the allergen extract, no consen-
sus was achieved regarding the value of these molecular
compounds to better identify the sensitisation profile of
patients allergic to mites (item number 31). Minor mites
such as Lepidoglyphus and Blomia represent a diagnostic
problem because of the lack of clinical trials using AIT for
them and consensus was not reached on this point. Never-
theless, in circumstances where sensitisation to Dermato-
phagoides and minor mites coexists and clinical relevance
for both types of mites is suspected, a vaccine containing
both species of mites could be suitable.
Participants also gave their opinion on mould and
animal dander allergy in this section. As far as mould
allergy is concerned, Quantification of Alt a 1 in the
vaccine is highly recommended, even after not reaching
consensus with respect to the need for quantifying serum
specific IgE against this main allergen of Alternaria in sen-
sitised patients. In case of double sensitisation to mites
and Alternaria, no consensus was reached regarding the
value of the evaluation of symptoms after exposure to
both. Finally, in relation to animal dander sensitisation,
AIT with cat and dog epithelia has demonstrated its effi-
cacy and both may be used but no consensus was achieved
in case of animals different from cat and dog.
Grass and olive pollen co-sensitisation
Consensus was achieved in 15/18 items, eight of them in
terms of agreement and seven in terms of disagreement
with the assertion mentioned (Table 3B). Results obtained
in this section of the questionnaire marked the limitations
of SPT and serum specific IgE against grass and olive pol-
lens as complete allergenic sources for clearly establishing
the allergenic profile of these patients. However, perform-
ing specific IgE against specific allergens such as Phl p 1,
Phl p 5 and Ole e 1, considered as markers of primary
Table 3 Items included in the questionnaire about “Olive and grass pollen allergy” (3A) and results (3B)
3A) 3B)
Items Mean Median % Panellists IQ Result
Epidemiology
51- All olive-grass cosensitised patients are equal if they are from the same geographic
area
2.15 2 9.68 2 D
52- All olive-grass cosensitised patients are equal if they have the same size wheals 1.84 1 4.84 1.5 D
53- The genuine sensitisation components (Phl p 1–5 and Ole e 1) are suitable for
identifying phenotypes
7.1 7 11.29 1 A
Clinical relevance
54- Geographic and aerobiological data are very important in identifying the clinical
relevance of olive and grass cosensitised patients
7.29 7 11.29 1 A
55- In olive-grass cosensitised patients, skin-tests have major limitations in confirming the
clinical relevance
7.18 7.5 16.13 1 A
56- A higher level of olive IgE than grass (or vice versa) is useful to highlight the clinical
relevance in cosensitised patients
4.08 3 45 2 NC
57- Confirmation of true sensitisation to olive or grass requires an IgE against genuine
components
7.56 8 8.06 1 A
58- The clinical relevance in olive-grass cosensitised patients can only be defined by
organ-specific provocation tests
3.19 3 25.81 2 D
Therapeutic strategy (Immunotherapy indication)
59- The identification of the relevant allergenic source in patients cosensitised to grass
and olive is essential before prescribing immunotherapy
7.98 8 4.84 1 A
60- The demonstrated efficacy in grass immunotherapy is the same as 50% mixture with
olive
2.92 3 20 1 D
61- In the case of olive-grass cosensitised patients, it is preferable to formulate persona-
lised mixes (variable percentages of the two extracts)
4.52 5 71.67 4 NC
62- As grass and olive are complex extracts, the dosage of individual allergens in
immunotherapy would be appropriate
7.05 7 10 1 A
63- The olive-grass cosensitised patient should not receive immunotherapy until more ef-
ficacy data is obtained
2.55 2 14.52 2 D
Therapeutic strategy (Immunotherapy formulation)
64- The lack of knowledge of therapeutic doses makes the formulation of mixtures
difficult
6.82 7 27.42 2 A
65- It is correct to formulate olive-grass personalised mixes depending on the size of the
wheal
2.53 2 22.58 2 D
66- It is preferable to formulate olive-grass personalised mixes (varying percentages of
the two extracts) in proportion to the IgE amount corresponding to the two extracts
3.72 3 46.67 3.5 NC
67- If the manufacturer guarantees the individual doses of allergens, mixtures of different
Poaceae and olive varieties are irrelevant
6.95 7 23.33 1 A
68- Grass and olive personalised mixtures (varying percentages of the two extracts)
should never be used
3.92 3 30 2 D
A = Agreement; D = Disagreement; NC = No Consensus; IQ = Interquartile range.
% panellists = percentage of panellists out of the median region.
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sitisation pattern and cross-reactivity without clinical rele-
vance. Selection of the vaccine should be made depending
on such results, and only when double genuine sensitisa-
tion assessed by molecular diagnosis was confirmed
should vaccination with both allergens be performed.
The use of personalised formulas with different per-
centages of olive and grass extracts in the same vaccine,
based on size of the wheal or the value of specific IgE, is
still a matter of debate and no consensus was reached.In fact, some panellists are still in favour of varying the
proportion of allergens for individual patients.
Other pollen (weeds and trees) polysensitisation profile
Participants are aware of clinical problems in identifying
relevant allergens in areas with high and varied pollen ex-
posure and overlapping pollination periods. For that reason,
only 15 out of 20 items agreed, 13 in a positive way and 2
in a negative one (Table 4B). The lack of a clearly estab-
lished seasonal pattern for some pollen hinders the
Table 4 Items included in the questionnaire about “Allergy to other pollens” (4A) and results (4B)
4A) 4B)
Items Mean Median % Panellists IQ Result
Epidemiology
69- Pollen respiratory allergy does not always have a seasonal character 7.79 8 8.06 2 A
70- In the allergologic diagnosis, it is essential to know the allergenic sources and
preferential exposure calendars from the geographic area
8.37 8.5 0 1 A
71- In the allergologic diagnosis, it is essential to know the sensitisation prevalence to
different allergenic molecules from the geographical area
7.77 8 6.45 2 A
72- It is essential to know the aerobiology area: more captures are needed 7.81 8 8.06 2 A
Clinical relevance
73- The diagnosis of allergy to Parietaria can sometimes be hampered by the co-
sensitisation to other allergen sources, such as dust mites
6.84 7 25.81 2 A
74- Sensitisation to Parietaria pollen represents a major challenge for the establishment
of clinical relevance, because pollination coincides with other relevant allergenic sources
7.35 7.5 12.9 1 A
75- Clinical data (symptoms, time of symptoms, their duration) and aerobiological data
are the most important tools for the diagnosis of primary sensitisation sources in patients
sensitised to multiple pollens
6.85 7 20 1 A
76- In pollinic polysensitised patients, panallergen skin-tests (profilin, LTP and polcalcin)
are useful for selecting relevant allergens
6.82 8 25.81 2 A
77- The molecular diagnosis does not provide more information than skin-tests, as most
sensitisation is due to relevant molecular allergens rather than panallergens
4.85 3 48.33 4 NC
78- In a polysensitised patient, the presence of symptoms during the pollinic period of
given pollen does not imply clinical relevance of this allergenic source
5.22 5.5 88.33 4 NC
79- Molecular diagnostics is limited by the supply of molecular constituents of low
prevalence pollens
6.87 7 11.67 1 A
Therapeutic strategy
80- Immunotherapy is contraindicated in polysensitised patients with more than two
clinically relevant pollen types
2.66 2.5 17.74 2 D
81- Patients polysensitised to pollens with polcalcin sensitisation do not benefit from
treatment with immunotherapy because they have a higher number of reactions
4.1 5 45 2 NC
82- The administration of more than one vaccine could be indicated for patients
sensitised to more than one relevant allergenic source
6.63 7 20 0 A
83- Immunotherapy prescription with different allergenic sources is only justified in the
case that pollination periods from such sources do not coincide
2.92 3 22.58 1 D
84- When prescribing immunotherapy with a mixture of several allergenic sources, only
those pollens with significant exposure should be considered
7.07 7 11.67 0 A
85- In areas where grass and olive are prevalent allergens, if profilin is positive, only grass
must be included in the vaccine, although it is also common to find sensitisation to
other pollens as well
4.03 3 35 3.5 NC
86- If mixtures of several allergenic sources are used in immunotherapy, they should
include a higher percentage, depending on the clinical relevance of each geographical
area
4.58 5 66.67 4 NC
87- Immunotherapy would only be indicated if quality extracts for these pollens exist 7.81 8 6.45 2 A
88- The efficacy of immunotherapy is associated with an early indication 7.31 7.5 19.35 1 A
A = Agreement; D = Disagreement; NC = No Consensus; IQ = Interquartile range.
% panellists = percentage of panellists out of the median region.
Vidal et al. Clinical and Translational Allergy 2014, 4:36 Page 7 of 12
http://www.ctajournal.com/content/4/1/36diagnosis. And, in this case, molecular diagnosis is of little
help because of the low availability of molecular com-
pounds of pollens apart from grass and olive. Interpretation
of polcalcin sensitisation is not always possible and could
act as a confounding factor. For that reason, a deep know-
ledge of all allergenic sources from each zone (Figure 3), in-
cluding pollen calendars and specific taxons is essential. Noconsensus was achieved regarding the utility of the sIgE to
panallergens (profilin or polcalcin) in complex pollen areas
because of difficulties in recognising the relevant and pri-
mary sensitiser. The same occurred when profilin or polcal-
cin were assessed as relevant grass sensitisation markers
that would allow excluding other allergens in the AIT. In
the case of mixing several allergens, a consensus was
Figure 2 Valuation scale of professional criteria or clinical recommendations proposed to be judged. 1–3: I disagree with the assertion
(a lower score indicates greater level of disagreement); 4–6: Neither agree nor disagree with the assertion; I do not have fully defined criteria
about the question (choose 4 or 6 if closer to disagreement or to agreement, respectively); 7–9: I agree with the assertion (a greater score
indicates greater level of agreement).
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strated clinical relevance, notable exposure, no more than 3
allergens in the same vaccine, and always with quality ex-
tracts. Defining the composition of the mixtures is an on-
going problem without consensus. An accepted alternative
is the possibility to administer ≥2 vaccines in some cases
(although in practice it is assumed that the administration
of 2 vaccines is not always acceptable due to the economic
cost).
Discussion
General approach to polysensitised subjects
Polysensitisation is a serious problem in countries like
Spain, where different allergenic sources may influenceFigure 3 Main geographical areas based on patients’ sensitisation proclinical symptoms in allergic patients. Allergists from
Spain are used to dealing with this problem but, on
some occasions, lack of evidence could make them hesi-
tate about the best treatment option in each case. Other
Mediterranean countries such as Italy or Greece share
the same problem [17,18]. This lack of scientific evi-
dence led us to promote the present Consensus Report
aiming at helping allergists with diagnosis and treatment
in complex areas from an allergological point of view.
As authors, we are aware of the limitations of expert
opinion statements and for this reason the well-known
and highly contrasted Delphi Method was used to gather
and analyse the proposed items reflecting common
problems in clinical practice. As a whole, 83% of thefile.
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we consider each group of items separately. It seems that
decisions are easier when considering general situations
(91.6% agreement) than when deciding specific solutions
for specific allergens. It seems that experts have the skills
to decide how to act but they fail to agree when diagnos-
tic tools are limited or are not available. According to
this, the lowest level of agreement, 75%, was reached in
the “other pollen sensitisation profile”, reflecting difficul-
ties in recognising relevant allergens in polysensitised
patients in those areas, such as Mediterranean Spanish
coast, with a high number of allergens and high allergen
pressure [19].
According to what has been published, experts agree
with respect to the limited value of SPT in firmly recog-
nising relevant allergens [20]. SPT is commonly used in
daily clinical practice because of its simplicity and reli-
ability to quickly identify IgE sensitisation to inhalant al-
lergens. The relationship between SPT wheal sizes and
the clinical relevance of positive results is debatable
[21,22] and, consequently, it is understandable that con-
sensus was not reached on this point. In fact, many fac-
tors can influence SPT results. A seasonal variation in
wheal sizes has been described for several allergens [23].
The site where SPTs are performed may influence the
results. The ulnar side of the arm is more reactive than
the radial side, and the antecubital fossa is more reactive
than the wrist [24]. Finally, the SPT technique may influ-
ence the size of the wheal reaction [22]. Experts consider
serum specific IgE more reliable in recognising clinically
relevant allergens, as it has been considered by others
[25]. Recent advances in molecular diagnosis are supposed
to help allergists in the recognition of genuine sensitisa-
tions, and experts agree on the value of this diagnostic
tool, but the lack of a cut-off level is a limitation of the
test. The fact that sensitisations are not always accompan-
ied by clinical symptoms is well-recognised [26]. For that
reason, experts agree that polysensitisation is not the same
as polyallergy, meaning that polyallergic patients are
only those with clinically relevant symptoms related to
allergen exposure. To identify relevant allergens, symptom
scores are useful in a similar way than when performing
clinical trials. The recognition of a cause-effect relation-
ship should be done according to the allergen exposure.
Aerobiological information is essential for this purpose.
Even though allergen challenge tests can be useful in cli-
nical trials and even in proving the clinical relevance of
purified allergens (profilin, polcalcin and so on) [27], they
are time-consuming, and therefore the implementation of
these tests in daily clinical practice before prescribing AIT
is not necessary. The use of allergenic extracts with pro-
ven efficacy is strongly supported and clinical studies
should follow the guidelines of regulatory agencies [13].
Taking into account differences among products fromdifferent allergen manufacturers, each one must perform
their own clinical trials for every single product, since re-
sults from one study with one allergen cannot be extra-
polated to a different allergen, or even the same allergen
produced by another manufacturer [28-30]. Finally, when
considering mixing allergens and following EMA sug-
gestions, non-related allergens with possible enzymatic
activity should not be mixed; even for related allergens, no
more than three should be used in the vaccine.
Sensitisation profile involving mite, animal dander and
moulds
According to what has been accepted in the general ap-
proach section, experts agree with the idea of knowing
the species of mites predominant in one area. It is well-
known that mites are not uniformly distributed all over
the world and, even for the same Dermatophagoides
genus, distributions of pteronyssinus and farinae species
vary from place to place [7,31]. However, the high degree
of cross-reactivity proven between them [7,32] seems not
to be a problem when selecting the composition of AIT.
That is not the case for minor mites. The lack of cross-
reactivity among them and Dermatophagoides [33-35]
represents a problem difficult to resolve. Thus, while
experts could recommend the prescription of a vaccine
containing minor mites and Dermatophagoides in equal
proportions, they recognise the need for more studies
showing clinical efficacy of AIT with minor mites alone
before strongly supporting their use as a therapeutic op-
tion. Consequently, no agreement was achieved on this
specific item.
Molecular diagnosis, as far as mite and mould allergy
is concerned, seems to be of little or no value, and there-
fore experts show no agreement regarding the need for
measuring sIgE before prescribing AIT with them. In
fact, no consensus was achieved when specifically asked
about the need of measuring sIgE against Der p 1, Der p
2 or Alt a 1. However, quantification of major molecular
compounds of both mites and moulds in the vaccine is
evaluated positively by participants. One possible expla-
nation for these contradictory results may be related to
the recent advances in the recognition of the pattern of
sensitisation against Der p 1 and Der p 2 and the lack of
correlation between them [7]. More studies are needed
to balance the importance of both molecules in each pa-
tient, but in the meantime quantification of major aller-
gen compounds in the vaccine could be useful to explain
adverse effects or even efficacy.
Biological standardisation of moulds is difficult [36] but
participants consider Alternaria and Aspergillus spp the
only relevant allergens from a respiratory point of view.
Moreover, only Alternaria could be considered as a poten-
tial allergen for AIT. For that reason mixture of moulds
should never be an option accepted by experts. The main
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mites. There is no consensus regarding the utility of symp-
tom and medication scores or the recognition of sources
of exposure when dealing with patients sensitised to mites
and Alternaria. If needed, more than one vaccine could be
used and this recommendation applies not only for mites
and Alternaria but also for animal dander allergy. Vac-
cines with cat or dog allergens may be used if these aller-
gens are clinically relevant and avoidance is not an option.
AIT with horse extract is not supported by all experts,
and no consensus was reached despite proven efficacy.
The main limitation could be that there was only one pub-
lished study when the questionnaire was done, and it is
not a double-blind placebo-controlled study [37]. Re-
cently, Nanda and Wasam have published their experience
with a horse extract at different doses in eight patients,
with positive results [38].
Grass and olive pollen cosensitisation
As far as grass and olive pollen is concerned, participants
agree that measurement of specific IgE to Phl p1, Phl p 5
and Ole e 1, molecular compounds considered as pheno-
typic markers of genuine grass and olive pollen sensitisa-
tion, respectively are useful in deciding the composition of
AIT. In addition, some allergens considered minor be-
cause of their lower prevalence in terms of sensitisation,
such as Ole e 7 and Ole e 9, could be of importance in re-
gions with high allergenic pressure to olive pollen. More-
over, the presence of high levels of specific IgE against
them could explain some serious adverse reactions during
AIT with olive pollen extracts [38]. AIT is claimed to be a
first line therapy option in patients sensitised to grass and
olive, if both are clinically relevant. The low cross reacti-
vity between pollens of different species, including olea-
ceae and grass [39,40], but particularly the presence of
genuine sensitizers [41,42], justifies the consensus on the
suitability of individual dosages of each extract. Finally, no
consensus was achieved when experts were asked about
the use of personalised immunotherapy. The term “perso-
nalised” was used to express formulations with different
proportions of each allergen as opposed to the idea of
fixed combinations in equal proportions (50%-50%), but
the statement recorded was not clearly defined and could
have been misunderstood.
Other pollen (weeds and trees) polysensitisation profiles
Pollens from trees and weeds such as Betula spp, Platanus
spp, Cupressus spp, Artemisia spp, Chenopodium spp,
Parietaria spp, Plantago lanceolata and Salsola kali may
induce IgE sensitisation in atopic subjects in exposed
individuals in Spain and other Mediterranean countries
[43]. Exposure to these pollens varies from place to place.
This is why allergists from different regions may have
different opinions about how to deal with polysensitisedsubjects, depending on the different taxons present in a
particular area. In fact, the level of consensus was lower in
this section compared with the others. It is noteworthy that
experts do not have a recommendation regarding the
usefulness of molecular diagnosis because of difficulties in
distinguishing primary sensitisation and cross-reactivities.
Even symptom and medication scores are of little value.
Polcalcin has been considered a confusion factor, but the
actual meaning of polcalcin sensitisation is far from known.
There are no published articles investigating the prognostic
value of such sensitisation or the possible interference on
efficacy or safety of immunotherapy. As regards profilin,
some authors have demonstrated a relationship between
profilin sensitisation and symptoms [19] while others con-
sider profilin sensitisation a confounding factor that could
interfere with immunotherapy efficacy, because of its role
as a confounding factor for the diagnosis [6]. More studies
are needed to clarify these questions. In the meanwhile,
patients allergic to more than one non-related pollen could
be treated with more than one high-quality vaccine or a
mixture of pollens with clinically relevant exposure.
Conclusion
In conclusion, choosing the best allergen for AIT in
polysensitized patients is a difficult task. Consensus like
the one presented here could be of help to allergists be-
fore making decisions on AIT composition. From the re-
sults of this survey we can conclude that:
a. SPTs are not enough to accurately diagnose allergy
in polysensitised patients.
b. An approach to molecular diagnosis seems to be
useful in pollen-allergic patients if all relevant
molecules were available.
c. AIT prescription should be based on scientific
evidence, and only be indicated if relevant allergens
are identified.
d. Data from clinical records and knowledge of allergen
exposure in each area are essential to define AIT
composition.
e. No more than three allergenic sources should be
mixed in the same vaccine.
f. Each vaccine should have its own safety and efficacy
studies.
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